Will generic Wellbutrin live up to brand?

It's not often that we get data on patients switching from a branded med to a rival generic. But complaints about Teva Pharmaceutical Industries' version of the antidepressant Wellbutrin XL drove FDA to study the matter. The generics giant promised the agency it would run a head-to-head trial, pitting its version against the brand-name product.

Well, Teva has now proposed the parameters of that clinical trial, and Biovail--which makes the brand-name version--is objecting. Biovail claims that the trial's design--138 patients and 24-day duration--would be inadequate for a true compare-and-contrast look at the two medications. The Canadian drugmaker says it learned of this trial design in a December 2 news article.

The trial's outcome could be big for Biovail, which bought out GlaxoSmithKline's U.S. rights to Wellbutrin XL last year for $510 million. If Teva's version were proven to be somehow inferior to the brand-name product, then Biovail might reap millions in additional sales. At one time Biovail reaped $2 billion a year from Wellbutrin XL, Reuters notes, but that was before generic competition ate into sales.

But the trial--provided its design was considered sufficient by objective third parties--could end up being a big deal for brand-name and generics drugmakers alike. If a true, well-crafted, head-to-head trial found statistically significant differences between a branded product and a generic copycat, that could throw the whole generic-substitution thing way off whack--and soften the blow of generic competition in a big way.

- read the Reuters piece

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.